KRAS

#Advertorial #HUB Organoids #KRAS #Organoids

KRAS is no longer undruggable. Is your preclinical model ready?

In this paid-for advertorial for the Fall 2026 issue of DDW, HUB Organoids shares insight on KRAS inhibitor development.  KRAS inhibitor development has moved past single-allele chemistry into pan-RAS and combination strategies. HUB Organoids’ patient-derived organoid platform gives your programme the resistance data, allele breadth, and combination… Read More

#Exclusive Content

Dollar sign on a tablet
#Collaboration #KRAS #MSD #Oncology #SciBrunch Therapeutics

MSD buys oral KRAS G12D (ON) inhibitor for $2.13 billion

SciBrunch Therapeutics and MSD (or Merck & Co) have entered into an exclusive global license agreement for SPR2015, an investigational preclinical oral KRAS G12D (ON) inhibitor.  Under the agreement, SciBrunch has granted MSD exclusive rights to develop, manufacture and commercialise SPR2015 worldwide.   SciBrunch will receive… Read More

#Business & Investment #News

KRAS
#Award #KRAS #Oncology #Pancreatic cancer #Revolution Medicines

$1 million Stephenson Global Prize honours pioneering KRAS research

Kevan Shokat has been named the 2026 Stephenson Global Prize Laureate, receiving $1 million for his pioneering contributions to pancreatic cancer research.   His discoveries helped transform decades of scientific thinking about KRAS, one of cancer’s most important and historically difficult-to-target drivers, and usher in a new generation… Read More

#Cancer Research #News #Trending News

KRAS
#Champions Oncology #Drug discovery #KRAS #Oncology #Patient-derived tumour models #Tumour models #Webinar

Webinar explores resistance to Pan-RAS(ON) inhibition

KRAS mutations are among the most prevalent oncogenic drivers in solid tumours, yet predicting which patients will respond to targeted therapy — and understanding why resistance inevitably emerges — remains one of the central challenges in oncology drug development. ‘Cracking KRAS: Decoding Sensitivity and Resistance to Pan-RAS(ON) Inhibition Across Patient-Derived… Read More

#News

#Elicio Therapeutics #KRAS #Oncology #Pancreatic cancer #Phase II trial

Elicio refines its Phase III strategy for ELI-002 7P in pancreatic cancer

Elicio Therapeutics has reported that its Phase II AMPLIFY-7P study evaluating ELI-002 7P in patients with adjuvant mKRAS-driven pancreatic ductal adenocarcinoma (PDAC) did not meet its endpoint of disease-free survival (DFS).   However, the company says landmark analyses during active ELI-002 7P treatment indicated early treatment benefit. Post-hoc… Read More

#Cancer Research #News

Test for KRAS mutation
#Champions Oncology #Drug discovery #KRAS #Oncology #Patient-derived tumour models #Tumour models #Webinar

Lessons from 50+ patient-derived KRAS-mutant tumour models

KRAS mutations are among the most prevalent oncogenic drivers in solid tumours, yet predicting which patients will respond to targeted therapy — and understanding why resistance inevitably emerges — remains one of the central challenges in oncology drug development. ‘Cracking KRAS: Decoding Sensitivity and Resistance to Pan-RAS(ON) Inhibition Across Patient-Derived… Read More

#News

#Champions Oncology #Drug discovery #KRAS #Oncology #Patient-derived tumour models #Tumour models #Webinar

Decoding Pan-RAS(ON) inhibitor activity across KRAS models: Webinar

KRAS mutations are among the most prevalent oncogenic drivers in solid tumours, yet predicting which patients will respond to targeted therapy — and understanding why resistance inevitably emerges — remains one of the central challenges in oncology drug development. ‘Cracking KRAS: Decoding Sensitivity and Resistance to Pan-RAS(ON) Inhibition Across Patient-Derived… Read More

#News

Cancer tumour
#Champions Oncology #Drug discovery #KRAS #Oncology #Patient-derived tumour models #Tumour models #Webinar

Cracking sensitivity and resistance to Pan-RAS(ON) inhibition with KRAS

KRAS mutations are among the most prevalent oncogenic drivers in solid tumours, yet predicting which patients will respond to targeted therapy — and understanding why resistance inevitably emerges — remains one of the central challenges in oncology drug development. ‘Cracking KRAS: Decoding Sensitivity and Resistance to Pan-RAS(ON) Inhibition Across Patient-Derived… Read More

#News

#Champions Oncology #Drug discovery #KRAS #Oncology #Patient-derived tumour models #Tumour models #Webinar

Webinar: Decoding sensitivity and resistance to Pan-RAS(ON) inhibition

KRAS mutations are among the most prevalent oncogenic drivers in solid tumours, yet predicting which patients will respond to targeted therapy — and understanding why resistance inevitably emerges — remains one of the central challenges in oncology drug development. ‘Cracking KRAS: Decoding Sensitivity and Resistance to Pan-RAS(ON) Inhibition Across Patient-Derived… Read More

#News

#Champions Oncology #Drug discovery #KRAS #Oncology #Patient-derived tumour models #Tumour models #Webinar

Cracking KRAS: Decoding Sensitivity and Resistance to Pan-RAS(ON) Inhibition Across Patient-Derived Tumour Models

KRAS mutations are among the most prevalent oncogenic drivers in solid tumours, yet predicting which patients will respond to targeted therapy — and understanding why resistance inevitably emerges — remains one of the central challenges in oncology drug development. ‘Cracking KRAS: Decoding Sensitivity and Resistance to Pan-RAS(ON) Inhibition Across Patient-Derived… Read More

Webinar date:
Supported by Champions Oncology
#Webinars

KRAS
#Cancer research #Clinical trial #KRAS #Protein

Targeting the undruggable protein: What is the potential for KRAS inhibitors? 

Diana Turner explores the latest KRAS breakthroughs and how our understanding of this illusive protein has developed in recent years.  In September 2025, the inaugural Stephenson Global Prize was awarded to Dr Frank McCormick, Professor at the UCSF Helen Diller Family Comprehensive Cancer Center, for “groundbreaking discoveries that have… Read More

#Cancer Research #Exclusive Content

Cancer research
#Antibody drug conjugate (ADC) #Cancer research #CAR T-cell therapy #KRAS #Radiopharmaceuticals

New tactics against hard-to-treat cancers

It is an exciting time in cancer drug discovery. Seven in 10 people now survive their cancer five years or more, up from only half in the mid-70s, according to the American Cancer Society’s 2026 Cancer Statistics.  New modalities, like radiopharmaceuticals, alongside new drug targets, like KRAS mutations, are resulting… Read More

#Cancer Research #Exclusive Content

Tumour microenvironment
#Insilico Medicine #KRAS #Oncology #Solid tumours

Insilico Medicine nominates pan-KRAS preclinical candidate

Insilico Medicine has nominated ISM6166 as a preclinical candidate, a potent, oral pan-KRAS inhibitor designed to treat a broad spectrum of solid tumours.  Among the Ras family of oncogenes, KRAS is one of the most frequently altered drivers in human cancer, playing a key role in regulating… Read More

#Cancer Research #News

#Artificial intelligence (AI) #Colorectal cancer #KRAS #Oncology #Oxford Drug Design

Oxford Drug Design validates cancer therapeutic mechanism

AI drug discovery company Oxford Drug Design has successfully completed in vivo validation of a novel therapeutic approach targeting multiple tumour types. In studies using a genetically engineered mouse model that replicates the earliest mutational events in colorectal cancer, Oxford Drug Design’s lead compound demonstrated statistically significant anti-tumour… Read More

#Cancer Research #News

#KRAS #Pancreatic cancer

McCormick wins Stephenson Global Prize for ‘innovative’ research 

The inaugural Stephenson Global Prize has been awarded to Dr Frank McCormick for his groundbreaking discoveries into pancreatic cancer.  The Stephenson Global Prize, presented for the first time in Boston, Massachusetts, was established to reward visionary researchers with resources to accelerate discoveries that could change the trajectory… Read More

#News

Pancreatic cancer
#Autophagy #Cancer Research UK #KRAS #Oncology #Pancreatic cancer

Autophagy disruption provides clues to cancer development

Scientists have uncovered dementia-like behaviour in pancreas cells at risk of turning into cancer.   The findings provide clues that could help in the treatment and prevention of pancreatic cancer, a difficult-to-treat disease linked to 6,900 deaths in the UK every year.   The research was… Read More

#Cancer Research #News